Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma SA ( (FR:IPH) ) has issued an update.
Innate Pharma announced it will host an analyst and investor event on October 28, 2025, focusing on its lead product, lacutamab, which is progressing towards potential accelerated approval in Sézary syndrome (SS) and the initiation of a confirmatory Phase 3 trial. The event will feature insights from T-cell lymphoma expert Dr. Pierluigi Porcu on the Phase 2 TELLOMAK trial results and market analysis from ZS Associates. Innate Pharma’s management will discuss the regulatory pathway and commercial opportunities for lacutamab, highlighting its potential to improve outcomes for patients with cutaneous T-cell lymphoma (CTCL) and create value for shareholders.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its antibody-engineering expertise to create innovative therapeutic approaches, including Antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs), and multi-specific NK Cell Engagers through its proprietary ANKET® platform. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. It is listed on Euronext Paris and Nasdaq.
Average Trading Volume: 202,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: €154.8M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.